MEDSIR, a leading international company in oncology research, has announced the results of the PHERGuide study during the 2025 San Antonio Breast Cancer Symposium (SABCS). This research, presented as an oral session during the congress, corresponds to a translational analysis of the PHERGain study and evaluates the correlation between the presence of circulating tumor DNA (ctDNA) in the blood, with the response to treatment and the risk of recurrence in patients with HER2+ early BC.

The EMPRESS study analyzes the potential benefit of giredestrant, a potent oral selective estrogen receptor degrader (SERD), in premenopausal women with early-stage ER+/HER2- breast cancer.  The results, presented during the ESMO 2025 congress, indicate a significant reduction in tumor markers compared to the current standard therapy.  These findings pave the way for exploring endocrine therapy-based strategies in premenopausal women without the need for ovarian function suppression,...

MEDSIR (Medica Scientia Innovation Research), a global leader in oncology research, and Ataraxis AI, a frontier laboratory developing artificial intelligence (AI)–powered prognostic tools for oncology, today announced a strategic collaboration to integrate artificial intelligence into multiple major international trials. These studies, with data from more than 1,000 patients across randomized clinical trials, aim to identify biomarkers that can optimize treatment strategies for breast cancer.